anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

152,161-152,220 of 319,975

filter-aware
01
Slide 1
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a 3-column layout to map programs to their respective 2020 momentum/milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a process-oriented chevron diagram to map strategic pillars to specific risk mitigation areas.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent clinical and preclinical development stages.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
06
Includes regulatory status callout.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a structured table format to define the disease context.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
08
Includes a visual demonstration of spastic diplegia in a patient.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
09
Includes clinical trial data (101A/102A) and baseline demographics for n=16 patients.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
10
The chart shows a box plot progression from baseline to week 56, demonstrating efficacy in reaching target ranges.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
11
The slide uses a color-coded heatmap to visualize patient improvement against baseline deficits.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
12
The slide outlines a strategic approach to trial design using four key pillars: Disease Burden, Known Impact, Look A-Like Condition, and Patient Feedback.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
13
The slide uses a process flow diagram to illustrate the clinical trial phases.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
14
The slide uses a geographic map to visualize addressable market segments based on genetic prevalence data.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Market Size1 hit
15
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
16
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
17
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
18
The slide uses a structured table format to define the clinical problem space.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
19
The slide uses a structured list format to contrast current care with its inadequacies.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
20
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The chart is a Kaplan-Meier survival curve showing significant improvement over the PBS negative control.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide outlines a sequential cohort design for a clinical trial, moving from IV to SC administration.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
23
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a simple table-like structure to define the problem space for a specific drug program.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
25
Includes medical imagery of kidney stones to illustrate the problem.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
26
Includes a before/after microscopy image showing crystal clearance.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
27
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
28
Aeglea BioTherapeutics | Investor Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Attention1 hit
02
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Attention1 hit
03
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Attention1 hit
04
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Attention1 hit
05
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Attention1 hit
06
The slide uses a two-tier structure to categorize partnerships by development stage.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
07
The slide uses a hub-and-spoke diagram to illustrate the central strategy of 'Targeting Cancer + Immunomodulation' supported by five distinct therapeutic platforms.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
08
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
09
The slide uses a Gantt-style visualization for clinical trial phases.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
10
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
11
Slide highlights key findings from a Nature publication regarding BNT111 vaccine efficacy and mechanism.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
12
Includes process flow diagram, flow cytometry plots, and a scatter plot showing TCR frequency.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
The slide uses a matrix-like structure to compare three clinical trial programs.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
14
The slide uses a visual representation of bispecific antibodies to explain their dual-target mechanism.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
15
Slide 15 of a BioNTech presentation, referencing SITC 2018.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
16
FIH = First-in-human; CPI = Checkpoint Inhibitor; ES-SCLC = Extensive-stage small cell lung cancer.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Satisfaction1 hit
17
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Satisfaction1 hit
18
The slide uses a linear process flow to illustrate the rapid development timeline of the BNT162 vaccine program.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide highlights BNT162b2 in a table and shows the SARS-COV-2 spike protein structure.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Satisfaction1 hit
20
The slide uses a bulleted list structure to justify a strategic decision in a clinical development program.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Satisfaction1 hit
21
The slide outlines the clinical trial protocol for the Pfizer-BioNTech COVID-19 vaccine.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Action1 hit
22
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Action1 hit
23
Includes specific manufacturing site counts and dose targets for 2020/2021.BioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Action1 hit
24
BioNTech | Results Presentation Deck | 28 slidesBioNTech | Results Presentation Deck | 28 slides · BioNTech
Conference presentation Investor relations Beat · Action1 hit
41
Includes guidance ranges for Q2 2020 estimates.Vertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
42
The slide uses a chevron graphic to visually separate historical data from future targets.Vertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
43
Vertex | IPO Presentation Deck | 48 slidesVertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
44
Vertex | IPO Presentation Deck | 48 slidesVertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
45
The R&D bars are stacked to show the split between R&D and Capitalized Software.Vertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
46
Vertex | IPO Presentation Deck | 48 slidesVertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
47
The table shows adjustments for D&A, interest, taxes, severance, and stock-based compensation.Vertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit
48
Vertex | IPO Presentation Deck | 48 slidesVertex | IPO Presentation Deck | 48 slides · Vertex
Pitch deck Investment bank 1 hit